Q3 2026 AMETEK Inc. Earnings Conference Call - AMETEK INC

Financial Performance:

• Q3 2026 total sales reached a record $2.22 billion (+17% YoY), driven by 10% organic growth and 7% contribution from acquisitions.
• Overall orders surged 35% YoY to $2.65 billion, with organic orders up 17%; backlog ended the quarter at a record $4.54 billion (+27% from year-end 2025).
• Operating income hit a record $595 million (+20% YoY); reported operating margins were 26.8% (+60 bps), while core margins expanded to 27.3% (+110 bps).
• EBITDA reached $704 million (+19% YoY) with an impressive 31.7% margin; Free Cash Flow (FCF) hit a record $527 million (+26% YoY) with FCF-to-net income conversion of 124%.
• Diluted EPS was a record $2.21 (+17% YoY), exceeding the prior guidance range.
• Interest expense increased to $40 million due to incremental borrowings for the Indicor acquisition; effective tax rate was 18.5%.
• Working capital improved to 17.3% of sales (160 bps improvement YoY).

Guidance and Future Outlook:

• Raised full-year 2026 guidance: Total sales expected to grow mid-teens (previously implied lower); EPS guidance raised to $8.53–$8.57 (+15% YoY) from $8.20–$8.30, reflecting ~$0.08 from Indicor.
• Q4 2026 outlook: Sales expected to grow low-20% range; adjusted EPS expected to be $2.26–$2.30 (+12–14% YoY).
• Full-year 2026 FCF conversion guidance raised to 115–120% of net income.
• Management anticipates strong momentum for 2027 with an 80% backlog shippability rate over the next 12 months.
• 2027 full-year organic sales expectations remain high single-digits for the company, with specific segment guidance: Process (mid-single), Aerospace/Defense (low-double), Power (mid-single), and Automation/Engineering Solutions (low-double).

Business Segments and Product Lines:

• Electronic Instruments Group (EIG): Record sales of $1.44B (+16% YoY); organic sales +9%; core margins 29.5% (+60 bps). Growth driven by semiconductor, aerospace, and power markets.
• Electromechanical Group (EMG): Record sales of $778M (+20% YoY); organic sales +13%; core margins hit record 27.5% (+210 bps). Growth balanced across aerospace, defense, med tech, and automation.
• Indicor Acquisition: Closed Q3; contributed ~$100M in Q3 sales and $0.08 EPS to full-year 2026 guidance; projected to be a ~$1.1B annual revenue stream at ~30% EBITDA margins.
• New Product Launches: Introduced "DPP Plus" digital process power UPS platform for mission-critical industrial and data center applications; noted 800-volt DC experimentation for data centers.
• Segment Performance: Paragon (MedTech) grew low-double digits; Ferro (Life Sciences) exceeded Year 1 profitability models; Semiconductor orders grew >30%.

Market and Competitive Landscape:

• Strong secular tailwinds identified in AI infrastructure, defense/energy security, medical technology, commercial aerospace, and precision automation.
• Geographic performance: U.S. grew low-double digits; Asia grew mid-20% (China outperforming); Europe was the weakest region with some timing headwinds.
• Semiconductor segment shows orders growing >30% against ~6% sales mix, driven by fab expansion and yield improvement needs.
• Aerospace backlog described as "very solid" with strong commercial OEM and aftermarket demand; defense shifted from discretionary to required spend, expanding globally (Europe, NATO allies).

Risks and Challenges:

• Inflation: Experienced ~3% inflation in the quarter; management confirmed pricing power allowed them to exceed inflation costs, maintaining positive price-cost spreads.
• Integration: Managing the transition of Indicor's 10 businesses into 8–10 Ametek units; mitigated risk via structured integration teams and "Ametek University" onboarding.
• Geopolitics: Conflicts in the Middle East and Russia; management views defense and energy security spending as "required," limiting downside risk to these sectors.
• Seasonality: Indicor viewed as having low seasonality, aiding predictability of Q4 and 2027 performance.

Management Commentary and Tone:

• Tone was highly confident and positive, describing results as "superb," "exceptional," and "outstanding."
• Emphasis on "disciplined operating model," "asset-light" structure, and high-quality earnings.
• Management confirmed the M&A pipeline is robust and the company is "full speed ahead" on acquisitions despite the Indicor integration.
• Highlighted 25% new product vitality for the year, indicating strong innovation.

Analyst Questions and Answers:

• Order Cadence: September was the strongest month for orders, setting a monthly record; October remained solid with sequential growth from Q2.
• Indicor Synergies: Target is 10–12% synergy over three years; 2027 outlook to be provided after the November/December budget process.
• Backlog Visibility: 80% of the $4.54B backlog is shippable within 12 months, providing strong visibility for 2027 revenue.
• MedTech/Electives: Paragon growth driven by new product wins and share gains rather than procedural volume; minimal impact from elective procedure deferrals observed.
• Margin Expansion: EMG's 210 bps core margin expansion driven by productivity and positive price-cost spreads; core incremental rates expected to remain >35% in 2026.
• M&A Strategy: Capital allocation priority 1 is strategic acquisitions; Priority 2 is opportunistic buybacks; Priority 3 is modest dividend growth.

Other Key Points:

• Total debt increased to $6.7B at Sept 30 (vs. $2.3B end of 2025) due to Indicor acquisition; net debt to EBITDA ratio is 2.1x.
• Capital expenditures for 2026 remain guided at ~$160M (2% of sales).
• Management reiterated that their niche, mission-critical products create high barriers to entry and switching costs.
• Specific mention of success in EUV optics (Zygo) and durable electronics for data analysis (Abaco) in the semiconductor space.